ABCG2 p.Gln126Thr
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 18253130
[PubMed]
Lemos C et al: "Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors."
No.
Sentence
Comment
45
Breedveld et al (2005) showed that Table 1 BCRP substrates and polymorphisms Substrates Classical anticancer drugs Novel targeted drugs Mitoxantrone Canertinib (CI-1033)a Anthracyclinesb Imatiniba Camptothecins Nilotiniba Antifolatesb Gefitiniba Erlotinib Flavopiridol Polymorphismsc Variant Amino-acid change Effect G34A Val12Met (V12M) No change C376T Gln126stop (Q126T) No active BCRP protein C421A Gln141Lys (Q141K) Decreased protein levels and drug resistance Increased gefitinib-associated toxicity (diarrhoea) Increased imatinib accumulation in vitro, but no changes in the pharmacokinetic parameters of imatinib in vivo G1322A Ser441Asn (S441N) Decreased protein levels and different subcellular localisation BCRP ¼ breast cancer resistance protein.
X
ABCG2 p.Gln126Thr 18253130:45:366
status: NEW115 Another SNP, the C376T, replaces glutamine by a stop codon at position 126 (Q126T), and was found in 3 out of the 124 Japanese population (Imai et al, 2002).
X
ABCG2 p.Gln126Thr 18253130:115:76
status: NEW